East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Pirfenidone Capsules USP, 267 mg. Aurobindo Pharma’s Pirfenidone Capsules, are an AB-rated generic equivalent to the reference listed drug (RLD), Esbriet Capsules, manufactured by Legacy Pharma, Inc.

Pirfenidone Capsules are indicated for the:

• Treatment of Idiopathic Pulmonary Fibrosis (IPF).